From bench to bedside, work in cell-based myocardial regeneration therapy

Journals Menu

Follow SCIRP

ISSN Print: 1937-6871
ISSN Online: 1937-688X
www.scirp.org/journal/jbise
E-mail: jbise@scirp.org

"From bench to bedside, work in cell-based myocardial regeneration therapy"
written by Shigeru Miyagawa, Yoshiki Sawa,
published by Journal of Biomedical Science and Engineering, Vol.7 No.2, 2014

has been cited by the following article(s):

[1]	CXCL4/PF4 is a predictive biomarker of cardiac differentiation potential of human induced pluripotent stem cells
	2019

[2]	Human skeletal muscle-derived stem/progenitor cells modified with connexin-43 prevent arrhythmia in rat post-infarction hearts and influence gene …
	2019

[3]	Human skeletal muscle-derived stem/progenitor cells modified with connexin-43 prevent arrhythmia in rat post-infarction hearts and influence gene expression …
	2019

[4]	Engineering the Micro-Environment Niche of Human Bone Marrow-Derived Mesenchymal Stem Cells for Enhanced Cardiac Tissue Regeneration
	2018

[5]	Nanofibers Based Tissue Engineering and Drug Delivery Approaches for Myocardial Regeneration
	Current pharmaceutical design, 2015

[1]	CXCL4/PF4 is a predictive biomarker of cardiac differentiation potential of human induced pluripotent stem cells Scientific Reports, 2019 DOI:10.1038/s41598-019-40915-w

[2]	CXCL4/PF4 is a predictive biomarker of cardiac differentiation potential of human induced pluripotent stem cells Scientific Reports, 2019 DOI:10.1038/s41598-019-40915-w

[3]	CXCL4/PF4 is a predictive biomarker of cardiac differentiation potential of human induced pluripotent stem cells Scientific Reports, 2019 DOI:10.1038/s41598-019-40915-w

Follow SCIRP